Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vesusten (also transliterated as Vezusten) is a tissue-specific peptide bioregulator consisting of a complex of low-molecular-weight polypeptides (not exceeding 10 kDa) extracted from bovine bladder tissue. Developed by PeptidPRO and manufactured by Samson-Med, Vesusten is designed for the pathogenetic treatment of overactive bladder (OAB) and lower urinary tract symptoms (LUTS). Unlike conventional symptomatic treatments such as antimuscarinics or beta-3 agonists, Vesusten acts at a tissue-specific level to restore the functional activity of the bladder wall, reduce detrusor hyperreflexia, and promote tissue repair and regeneration. It is administered via intramuscular injection and is approved in Russia for the treatment of overactive bladder and the prevention of recurrent chronic infectious cystitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vesusten.